Previous 10 | Next 10 |
Catalyst Pharmaceuticals (NASDAQ: CPRX ) is up 10% premarket on the heels of the announcement to terminate its common stock offering. More news on: Catalyst Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
CORAL GABLES, Fla., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) today announced that it will not conclude the offering of shares of its common stock announced on Wednesday, September 11, 2019. The Company believes that the culmination of an offe...
After it announced a secondary common stock offering, shares of Catalyst Pharmaceuticals (NASDAQ: CPRX) , a commercial-stage biopharma focused on rare diseases, fell as much as 16% in early-morning trading on Thursday. The stock was down about 11% as of 10:38 a.m. EST. Here are the details o...
Tocagen (NASDAQ: TOCA ) -82% after two-part immunotherapy flunks brain cancer study. More news on: Tocagen Inc., Adverum Biotechnologies, Inc., Celyad SA, Stocks on the move Read more ...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 121 weeks of public selections as part of this ongoing live forward-testing. In...
CORAL GABLES, Fla., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, toda...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 117 weeks of public selections as part of this ongoing live forward-testing. ...
Catalyst Pharmaceuticals ([[CPRX]]) reported very strong financial results for 2019’s second quarter, reporting 60% upside to the analyst consensus revenue estimate , also driving the company into profitable territory. We were a bit surprised with the muted reaction to the earnings pri...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 117 weeks of public selections as part of this ongoing live forward-testing. In...
Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2019 Earnings Conference Call August 8, 2019 8:30 A.M. ET Company Participants Alicia Grande - Chief Financial Officer Pat McEnany - Chairman and Chief Executive Officer Dan Brennan - Chief Commercial Officer Steve Miller - Chief Operati...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-03 11:30:04 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Underperform. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus :...